

CS Pharmaceuticals announces opening of Shanghai office to expand Regulatory and Clinical capabilities

London, England, September 13, 2021, CS Pharmaceuticals Ltd. (CSP), a British speciality pharmaceutical company focused on first- and best-in-class speciality therapeutics and treatments for rare diseases in China, are pleased to announce the opening of an office in Shanghai.

“We are delighted to announce the opening of our offices in Shanghai which will supplement our existing offices in Beijing. Shanghai has become a hub for the pharmaceutical and life sciences industry and has established itself as one of Asia Pacific’s leading high-end R&D, manufacturing, and outsourcing service centres. Shanghai is home to nearly 100,000 enterprises in the life sciences and pharmaceutical field”, said Darren Mercer, CEO of CSP.

In the future CSP’s business operations and finance functions will be based in Beijing and it’s Regulatory and Clinical functions will be based in Shanghai.

About CS Pharmaceuticals

CS Pharmaceuticals (CSP) is a British multinational pharmaceutical company focused on licensing Chinese commercialisation rights to Western rare disease and speciality medicines. The company, with its headquarters in London and offices in Beijing and Shanghai, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market. With its dedicated commercialisation platform, CSP is rapidly becoming a ‘go-to’ trusted licensing partner, expanding its portfolio of innovative rare disease and ophthalmology assets while making business easier for companies wishing to develop and commercialize their products in China.

www.cspharmaceuticals.com

Contacts

CS Pharmaceuticals
Darren Mercer, Chief Executive Officer

Tel: +44 (0) 2037 534691

